Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, Maryland, USA.
Clin Pharmacol Ther. 2011 Feb;89(2):167-9. doi: 10.1038/clpt.2010.283.
The development of topical products for dermatological diseases represents an untapped opportunity for the clinical pharmacologist. Assessment of bioavailability of topical drugs and its utility in weighing benefit vs. risk has been unique and challenging, compared with assessments for conventional systemic drugs. However, with continued advances in analytical methods and growing interests in discovering biomarkers, the future opportunities for clinical pharmacology to advance topical drug development processes are enormous and will be limited only by our drive and determination to push science forward.
皮肤科疾病局部用制剂的开发为临床药理学家提供了一个尚未开发的机会。与传统全身用药物评估相比，局部用药物的生物利用度评估及其在权衡获益与风险中的应用具有独特性和挑战性。然而，随着分析方法的不断进步和发现生物标志物的兴趣日益浓厚，临床药理学为推进局部药物开发过程提供的未来机会是巨大的，而我们推动科学前进的动力和决心将是唯一的限制。
